Skip to main content
Cellid Co., Ltd. logo

Cellid Co., Ltd. — Investor Relations & Filings

Ticker · 299660 ISIN · KR7299660001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2024-06-11 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 299660

About Cellid Co., Ltd.

http://www.cellid.co.kr

Cellid Co., Ltd. is a research and development biotechnology company focused on immunotherapeutic vaccines. The company's activities are centered on two proprietary technology platforms: CeliVax for anti-cancer immunotherapy and an adenovirus vector platform for infectious disease vaccines. The CeliVax platform is used to develop personalized vaccines that utilize a patient's own B cells and monocytes to target specific cancer antigens. The adenovirus vector platform enables the rapid development of safe, non-replicating viral vector vaccines, with a key application being its COVID-19 vaccine candidate. Cellid's pipeline is built upon these core technologies to address unmet medical needs in oncology and virology.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a capital increase (유상증자결정) for the company Cellid. It details amendments to the original filing, specifically regarding schedule changes and the name change of the lead underwriter. This document is a formal regulatory filing detailing capital structure changes and share issuance, which falls under the 'Share Issue/Capital Change' category.
2024-06-11 Korean
[기재정정]증권신고서(지분증권) (2024.07)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서(지분증권) 정정신고' (Securities Registration Statement Amendment) filed by Cellid Co., Ltd. in South Korea. It details amendments to a previously filed securities registration statement, including changes to the offering schedule, risk factors related to COVID-19 vaccine development, and updates to underwriter information. This is a formal regulatory filing required by the Financial Supervisory Service (FSS) in Korea for companies issuing new shares or securities. It does not fit into categories like Annual Reports, Earnings Releases, or Investor Presentations, but rather falls under the broader category of regulatory filings for capital raising activities.
2024-06-11 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is an official announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, location, target audience, and agenda for the meeting. Since this is an announcement of an event rather than the presentation slides themselves, and it does not fit into specific categories like earnings releases or financial reports, it is classified as a Regulatory Filing (RNS) which serves as the standard category for such corporate event notifications in this taxonomy.
2024-06-04 Korean
증권신고서(지분증권) (2024.07)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서' (Securities Registration Statement) filed with the Financial Services Commission (FSC) in South Korea. It details a capital increase (rights offering/public offering) for Cellid Co., Ltd., including comprehensive risk factors, financial status, and use of proceeds. This type of regulatory filing for capital raising is classified as a 'Capital/Financing Update' (CAP) within the provided schema.
2024-05-27 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is explicitly labeled as a '정정신고' (Amendment Report). It details changes to the number of stock options granted to employees and executives due to resignations. In the context of financial filings, reports regarding the issuance of stock options or changes to capital structure/share-based compensation that do not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes) are classified as Regulatory Filings (RNS) as they are mandatory disclosures to the financial authorities.
2024-05-24 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange regarding a 'Capital Increase Decision' (유상증자결정). It details the issuance of new shares, the purpose of funds, subscription methods, and underwriting details. This falls under the category of announcements regarding new share issues or capital changes.
2024-05-24 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.